Bio‐Orthogonal T Cell Targeting Strategy for Robustly Enhancing Cytotoxicity against Tumor Cells
Authors:
Abstract
T cells can kill tumor cells by cell surface immunological recognition, but low affinity for tumor‐associated antigens could lead to T cell off‐target effects. Herein, a universal T cell targeting strategy based on bio‐orthogonal chemistry and glycol‐metabolic engineering is introduced to enhance recognition and cytotoxicity of T cells in tumor immunotherapy. Three kinds of bicycle [6.1.0] nonyne (BCN)‐modified sugars are designed and synthesized, in which Ac4ManN‐BCN shows efficient incorporation into wide tumor cells with a BCN motif on surface glycans. Meanwhile, activated T cells are treated with Ac4GalNAz to introduce azide (N3) on the cell surface, initiating specific tumor targeting through a bio‐orthogonal click reaction between N3 and BCN. This artificial targeting strategy remarkably enhances recognition and migration of T cells to tumor cells, and increases the cytotoxicity 2 to 4 times for T cells against different kinds of tumor cells. Surprisingly, based on this strategy, the T cells even exhibit similar cytotoxicity with the chimeric antigen receptor T‐cell against Raji cells in vitro at the effector: target cell ratios (E:T) of 1:1. Such a universal bio‐orthogonal T cell‐targeting strategy might further broaden applications of T cell therapy against tumors and provide a new strategy for T cell modification.Keywords
Funding Information
- National Natural Science Foundation of China (81601552, 31571013)
- Natural Science Foundation of Guangdong Province (2016A030312006)
- Shenzhen Science and Technology Innovation Commission (JCYJ20170818154843625, JCYJ2017081816373945, JSGG20160331185422390, JCYJ20160429191503002, JCYJ20150403091443298, KQCX20140521115045447, JCYJ20150521094519473)
This publication has 27 references indexed in Scilit:
- Adoptive T cell therapy: An overview of obstacles and opportunitiesCancer, 2017
- Modeling Genomic Instability and Selection Pressure in a Mouse Model of MelanomaCell Reports, 2017
- Immunogenic cell death in cancer and infectious diseaseNature Reviews Immunology, 2016
- Driving CAR T-cells forwardNature Reviews Clinical Oncology, 2016
- Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall StreetThe Journal of Immunology, 2015
- The future of immune checkpoint therapyScience, 2015
- Exploiting the curative potential of adoptive T‐cell therapy for cancerImmunological Reviews, 2013
- Gene-engineered T cells for cancer therapyNature Reviews Cancer, 2013
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target ToxicityMolecular Therapy, 2013
- Selective pressures for and against genetic instability in cancer: a time-dependent problemJournal of The Royal Society Interface, 2007